Viz HCM

by Viz.ai  · Based in United States → — AI-powered disease detection and intelligent care coordination for Hypertrophic Cardiomyopathy.
Cardiology Emergency Medicine Hospital Medicine
Website
Claim this tool
Is this the maker? Claim the company →

Subscription-based
Regulatory Status Disclosed

Overview

Viz HCM is an AI-powered, mobile-based algorithm developed by Viz.ai, designed to advance disease detection and cardiac care coordination. It specializes in detecting suspected Hypertrophic Cardiomyopathy (HCM) from standard 12-lead electrocardiograms (ECGs) in real-time. Upon detection, Viz HCM automatically notifies the appropriate care specialists, facilitating timely follow-up and diagnosis. This solution helps healthcare providers identify patients who might otherwise go undiagnosed for years, significantly reducing the time to diagnosis and accelerating access to life-saving treatments. Viz HCM is part of the broader Viz.ai One platform, which leverages over 50 FDA-cleared AI algorithms to analyze various medical imaging data and streamline clinical workflows across multiple therapeutic areas.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered ECG analysis for Hypertrophic Cardiomyopathy (HCM) detection
  • Real-time disease detection from electrocardiograms
  • Mobile-based alerts and notifications to multidisciplinary care teams
  • Automated direction of patients to appropriate care specialists
  • Reduces time to diagnosis and treatment for HCM
  • Streamlines cardiac care coordination and clinical workflows
  • Seamless integration with existing clinical workflows, EHR, and PACS systems
  • Clinically validated with extensive real-world evidence and publications
  • Secure and compliant environment adhering to HIPAA, SOC 2 Type II, and GDPR standards

Use Cases

  • Early detection of Hypertrophic Cardiomyopathy (HCM) in general patient populations
  • Rapid triaging of patients with suspected HCM to specialized care
  • Improving patient follow-up and engagement for cardiac conditions
  • Accelerating diagnosis and treatment decisions in cardiology departments
  • Optimizing resource utilization and efficiency within hospitals and health systems
  • Enhancing communication and collaboration among multidisciplinary cardiac care teams

What Physicians Need to Know

Evidence Base
Viz HCM is an AI-powered algorithm trained on a diverse dataset of over 831,000 ECG exams from more than 300,000 individuals, covering both non-obstructive and obstructive HCM [1, 3]. The algorithm's development involved robust AI techniques and was validated against gold standards such as echocardiography and cardiac MRIs [1]. Viz.ai emphasizes evidence-based best practices and collaborates with leading experts in HCM management [2]. The broader Viz.ai platform is supported by over 100 published, peer-reviewed abstracts and manuscripts [11, 18].
Clinical Validation Studies
Viz HCM has undergone clinical validation, demonstrating its ability to detect suspected HCM. One prospective study across five centers identified new HCM patients through AI-based ECG alerts, with 7.8% of enrolled patients receiving a new HCM diagnosis [3]. Another study, published in JACC: Clinical Electrophysiology, evaluated Viz HCM across nearly 46,000 adult patients, flagging 2.76% with potential HCM [3]. Studies show the algorithm's performance is consistent across different racial backgrounds, suggesting generalizability [16]. Viz HCM is the only FDA-approved HCM algorithm on the market via a De Novo request [13].
Override Rate Data
Specific override rate data for Viz HCM was not explicitly found in the provided information.
Drug Interaction Checking
Drug interaction checking is not a primary function of Viz HCM, which focuses on AI-powered detection and care coordination for Hypertrophic Cardiomyopathy.
Differential Diagnosis Support
Viz HCM primarily focuses on detecting suspected HCM from ECGs and triaging patients to specialists [1, 13]. It aids in gaining clinical context alongside imaging results and can help 'rule in or rule out disease mimics' by providing a comprehensive patient view with EMR-enhanced data [13]. Viz Assist, a generative AI tool within the Viz.ai platform, offers guideline-based recommendations and automated chart summarization to support decision-making, which can indirectly assist in differential diagnosis by providing relevant context [22, 29].
Guideline Update Frequency
The explicit frequency of guideline updates for Viz HCM is not specified. However, Viz.ai emphasizes adherence to evidence-based best practices and collaborates with leading experts in HCM management [2]. The platform's AI algorithms are continuously developed and validated, and Viz Assist provides guideline-based recommendations [1, 3, 16, 22].
Clinical Workflow Integration
Viz HCM is designed for seamless integration into existing clinical workflows, analyzing all 12-lead ECGs across a health system [1, 5]. It integrates with EHR systems (e.g., Epic, Cerner), PACS, and radiology worklist systems to provide a comprehensive view of patient data, including ECG, echocardiogram, and cardiac MRI, all accessible via a HIPAA-compliant mobile app [9, 13]. This integration facilitates real-time communication and coordination among multidisciplinary care teams, accelerating diagnosis and treatment decisions [11].
Decision Audit Trail
While a specific 'Decision Audit Trail' feature name wasn't found, Viz.ai emphasizes security, compliance, and responsible AI. The company has successfully completed SOC 2 Type II + HIPAA audits, which include criteria for processing integrity, security, and data management practices, suggesting robust internal tracking and accountability for system actions and data [24].
Physician Tip

Leverage Viz HCM as an AI-powered 'second set of eyes' for early detection of suspected Hypertrophic Cardiomyopathy from routine ECGs, even in general patient populations without prior suspicion [3, 7]. Utilize the integrated platform to quickly access comprehensive patient data, including ECGs, echocardiograms, and cardiac MRIs, alongside EHR information, to streamline diagnostic workups and differentiate HCM from mimics [13]. Engage with the mobile communication features to coordinate care efficiently with specialists, accelerating patient triage and follow-up [1, 11]. Remember that while the AI flags suspected cases, clinical expertise remains paramount for definitive diagnosis and treatment decisions [16].

Viz HCM is part of the broader Viz.ai One platform, which offers extensive interoperability. It seamlessly integrates with major Electronic Health Record (EHR) systems like Epic and Cerner, Picture Archiving and Communication Systems (PACS), and radiology worklist systems [9, 13]. This allows for real-time data flow and a unified patient view across various clinical systems, enhancing care coordination and reducing manual data entry [9, 11]. The platform also supports mobile access for care teams, ensuring critical information and alerts are available on the go [1, 11].

Details

Category Cardiology AI, Clinical Decision Support & Reference
Pricing Subscription-based
  • Subscription-based for hospitals and health systems; CMS reimbursement available for CPT codes 0764T and 0765T (national payment rate $128.90, effective Jan 1, 2025); Contact vendor for enterprise pricing
DeploymentCloud-based platform, integrated into hospital IT systems (EHR, PACS).
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Yes AI-estimated

Viz HCM received De Novo authorization from the U.S. Food and Drug Administration (FDA) in August 2023, creating a new regulatory category for cardiovascular machine learning-based notification software. The broader Viz.ai platform features more than 50 FDA-cleared AI algorithms.
Integrations
EHR Not specified
Specialties Cardiology, Emergency Medicine, Hospital Medicine

What the Web Says

Viz HCM, a product of Viz.ai, is an AI-powered platform designed to improve the detection and management of hypertrophic cardiomyopathy (HCM) and other time-sensitive conditions like stroke and pulmonary embolism. It analyzes medical imaging and ECG data to provide real-time insights and coordinate care teams, aiming to reduce time to treatment and improve patient outcomes. The platform is widely adopted in hospitals and health systems, with physicians reporting a positive impact on workflow and patient care.

Overall: Positive

Strengths

  • Accelerates diagnosis and treatment for time-sensitive conditions like stroke and HCM.
  • Improves care coordination and communication among medical teams.
  • Reduces door-to-treatment times for conditions like stroke.
  • Offers reliable detection of critical findings on imaging.
  • Smooth onboarding process with minimal IT overhead for non-technical users.
  • Potential to uncover undiagnosed HCM and re-engage patients lost to follow-up.

Limitations

  • Enterprise-only pricing, making it inaccessible to individual physicians.
  • Not a general clinical decision support tool; does not replace bedside CDS functions like drug dosing or differential generation.
  • Occasional flagging of clinically insignificant findings (e.g., subsegmental PEs).
  • Some issues reported with SSO and user management.
  • Vendor support can be responsive but not always timely.
  • Can produce false positives, leading to additional work for radiologists.

Based on reviews from: Clinical AI Report, Comparably, CREAITIQUE, G2, FeaturedCustomers, Google Play, Reddit, Stock Titan, Diagnostic and Interventional Cardiology, Circulation: Heart Failure, UC Davis Health, Business Wire

Last updated: 2026-07-20

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Viz HCM

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Viz.ai
Viz.ai Launches Viz Pulmonary Suite, the First Comprehensive AI-Powered Solution Dedicated to Pulmonary Care Delivery
Viz.ai launched its Viz Pulmonary Suite, an AI-powered solution designed to streamline care delivery for pulmonary conditions by integrating acute and chronic pulmonary workflows into a single platform. Early results show reduced time to treatment and improved patient outcomes.
2026-05
Viz.ai
Viz.ai Earns Back-to-Back No. 1 Ranking in Black Book Survey of AI Clinical...
Viz.ai secured the top spot for the second consecutive year in Black Book's survey of AI Clinical Decision Support Solutions, reinforcing its leadership as healthcare shifts towards clinical AI.
2026-04
Business Wire
Viz.ai Announces Strategic Collaboration to Expand Access to AI-Powered Subdural Hemorrhage Care
Viz.ai announced a strategic collaboration with Johnson & Johnson to expand access to its AI-powered Subdural Hemorrhage software solution, aiming to improve early identification and streamline care pathways for chronic subdural hematoma.
2026-04
Viz.ai
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration
Viz.ai partnered with Cortechs.ai to expand into neurodegenerative disease care, starting with multiple sclerosis, by integrating Cortechs.ai's quantitative MRI analysis into the Viz Neuro Suite.
2026-07
Stock Titan
Three New Studies Show Viz.ai's Cardio Suite Speeds Detection of Cardiac Disease and Improves Patient Follow-Up
Three new studies presented at ACC.26 demonstrated that Viz HCM, Viz.ai's AI-powered ECG analysis solution, speeds the detection of hypertrophic cardiomyopathy (HCM) and improves patient follow-up.
2026-03
Viz.ai
Viz.ai Achieves ISO/IEC 42001 Certification, Setting the Standard for Agentic AI in Healthcare
Viz.ai achieved ISO/IEC 42001 certification, validating its enterprise-grade AI governance framework for safe and scalable agentic clinical workflows in healthcare.
2026-05
EMJ
AI-Enabled ECG Helps Identify Undiagnosed Hypertrophic Cardiomyopathy
New prospective data indicates that Viz HCM, an AI-enabled ECG screening tool, can be successfully implemented in real-world clinical settings to identify previously undiagnosed hypertrophic cardiomyopathy (HCM) patients.
2026-01
Business Wire
Viz.ai Launches Viz Agent Studio Enabling Health Systems to Build and Scale Their Own AI Care Pathways
Viz.ai launched Viz Agent Studio, a new capability within its Viz Oneu00ae Platform, allowing health systems to create and scale their own AI Care Pathways by translating clinical guidelines into workflows using natural language.
2026-03

Videos

Product demos, reviews, and walkthroughs for Viz HCM.

View all on YouTube

Frequently Asked Questions

Viz HCM is an AI-powered, mobile-based algorithm that integrates with your health system's existing infrastructure, analyzing 12-lead ECGs in real-time to detect suspected hypertrophic cardiomyopathy (HCM) cases. It then directs these patients to appropriate care specialists via a mobile app, aiming to reduce time to diagnosis and streamline care coordination.
Yes, Viz HCM received De Novo approval from the U.S. Food and Drug Administration (FDA) in August 2023, creating a new regulatory category for cardiovascular machine learning-based notification software. While Viz HCM serves as an assistive technology to enhance decision-making and care coordination, physicians retain ultimate clinical responsibility for patient care.
Alternatives to Viz HCM can include other AI imaging analysis platforms or EMR-integrated clinical decision support tools, such as Aidoc or Enlitic, which also enhance diagnostic capabilities. Viz.ai differentiates itself through its focus on time-sensitive conditions, a comprehensive care coordination platform with over 50 FDA-cleared algorithms across various specialties, and its proven impact on treatment times and patient outcomes.
Viz HCM is generally priced on an enterprise subscription basis, with costs negotiated directly with hospitals or health systems, varying based on the organization's size and the number of targeted diseases. It is typically funded through hospital operational budgets, with some Viz.ai modules having received Medicare reimbursement (NTAP) for specific use cases, which can help hospitals recoup costs.
Like all AI, Viz HCM's algorithms are trained on specific datasets and may have limitations in detecting rare conditions or performing optimally with atypical ECGs. Viz.ai states they go to great lengths to ensure their algorithms do not exhibit bias by using diverse training data. Physicians must understand the specific indications for which the AI is cleared and use their clinical judgment to interpret results, especially in complex cases.
Viz HCM adheres to strict HIPAA compliance standards, employing robust encryption, access controls, and de-identification protocols to protect patient health information. Viz.ai also maintains globally recognized certifications like SOC 2 Type II and ISO 27001, demonstrating a comprehensive security and privacy program with regular independent audits.
Viz.ai provides comprehensive onboarding and training for clinical staff through Viz Academy, which offers clinician-led product training and clinical education content. Ongoing support includes dedicated 24/7 on-call clinical specialists, implementation experts, and customer success teams to help optimize platform utilization and address queries.

Compare Viz HCM

VS
Viz HCM vs EchoNext
Cardiology AI Direct · 85/100
Viz HCM and EchoNext are highly comparable, both being FDA-cleared AI tools that analyze ECGs for cardiac conditions. Viz HCM specifically targets Hypertrophic Cardiomyopathy detection and care coordination,…
VS
Viz HCM vs PMcardio
Cardiology AI Adjacent · 70/100
Viz HCM is specifically designed for the detection and care coordination of Hypertrophic Cardiomyopathy (HCM) using ECG analysis, with FDA clearance and CMS reimbursement pathways. PMcardio, while also…
VS
Viz HCM vs Cardiomo
Cardiology AI Adjacent · 65/100
Viz HCM is an AI tool for hospitals to detect suspected Hypertrophic Cardiomyopathy from ECGs and coordinate care, aiming to reduce diagnosis time. Cardiomo, on the other hand,…
VS
Viz HCM vs KardiaPro
Cardiology AI Adjacent · 65/100
Viz HCM is designed for real-time, AI-powered detection of Hypertrophic Cardiomyopathy within hospital systems, focusing on acute diagnosis and care coordination. In contrast, KardiaPro is a web-based portal…

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

More from Viz.ai

ContaCT
Viz.AI
Neurology AI
Viz.ai is a pioneering AI-powered care coordination platform that accelerates disease detection and streamlines clinical workflows. With multiple FDA clearances, including the initial Viz.AI Contact application for stroke, it helps ensure patients receive timely treatment across over 1,700 hospitals globally.
Subscription-based
Viz AAA
Viz.ai
Cardiology AI
Viz AAA is the first FDA-cleared AI-powered solution by Viz.ai for the detection and triage of suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans, designed to accelerate diagnosis and care coordination.
Subscription model
Viz ANEURYSM
Viz.ai
Neurology AI
Viz ANEURYSM is an FDA-cleared AI-powered solution by Viz.ai that auto-detects suspected cerebral aneurysms in CT angiograms (CTAs), streamlining neurovascular care coordination and facilitating timely patient management.
Contact for pricing
Viz CTP
Viz.ai
Clinical Decision Support & Reference
Viz.ai is a pioneer in AI-powered disease detection and intelligent care coordination, leveraging over 50 FDA-cleared algorithms to analyze medical imaging and streamline clinical workflows for faster diagnosis and treatment.
Subscription model

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19

Investors who backed Viz HCM

Funded through the company that built this tool.

Scale Venture Partners
VC T3
Foster City, United States
$5M-$25M
Scale Venture Partners is a Foster City-based growth-stage software firm investing primarily in B2B SaaS, with a long track record of leading…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
AI Tool Finder
AI-powered search. Results may not be comprehensive.